{
    "relation": [
        [
            "Arms",
            "Placebo Comparator: Placebo Administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose may be increased to LY3009104 8 mg or 10 mg orally once daily for an additional 12 weeks.",
            "Experimental: 2 mg LY3009104 Administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose may be increased to LY3009104 8 mg or 10 mg orally once daily for an additional 12 weeks.",
            "Experimental: 4 mg LY3009104 Administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose may be increased to LY3009104 8 mg or 10 mg orally once daily for an additional 12 weeks.",
            "Experimental: 8 mg LY3009104 Administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, dose may be increased to LY3009104 10 mg orally once daily for an additional 12 weeks.",
            "Experimental: 10 mg LY3009104 Administered orally once daily for initial 12 weeks. At Week 12, depending on participant's response, LY3009104 10 mg orally once daily may be continued for an additional 12 weeks."
        ],
        [
            "Assigned Interventions",
            "Drug: Placebo Administered orally",
            "Drug: LY3009104 Administered orally Other Names: LY3009104 JAK1/JAK2 Inhibitor Janus Kinase 1/2 Inhibitor INCB028050",
            "Drug: LY3009104 Administered orally Other Names: LY3009104 JAK1/JAK2 Inhibitor Janus Kinase 1/2 Inhibitor INCB028050",
            "Drug: LY3009104 Administered orally Other Names: LY3009104 JAK1/JAK2 Inhibitor Janus Kinase 1/2 Inhibitor INCB028050",
            "Drug: LY3009104 Administered orally Other Names: LY3009104 JAK1/JAK2 Inhibitor Janus Kinase 1/2 Inhibitor INCB028050"
        ]
    ],
    "pageTitle": "A Phase 2b Study of LY3009104 in Participants With Moderate to Severe Psoriasis - Full Text View - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/NCT01490632?recr=Open&cond=%22Skin+Diseases%22&rank=1",
    "hasHeader": true,
    "headerPosition": "FIRST_ROW",
    "tableType": "RELATION",
    "tableNum": 3,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042988311.72/warc/CC-MAIN-20150728002308-00103-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 868553327,
    "recordOffset": 868539116,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "December 2012 (Final data collection date for primary outcome measure) Primary Completion Date: August 2014 Study Completion Date: December 2011 Study Start Date: 272 Enrollment: Quality of life and outcome assessments. Measures: Patient Reported Outcomes (PRO) [\u00a0Time\u00a0Frame:\u00a0Week 12, Week 24, and Week 92\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Efficacy of LY3009104 in participants with moderate to severe plaque psoriasis. Measure: Psoriasis Area and Severity Index (PASI) [\u00a0Time\u00a0Frame:\u00a0Week 12, Week 24, and Week 92\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Efficacy of LY3009104 in participants with moderate to severe plaque psoriasis. Measure: Static Physician Global Assessment (sPGA) [\u00a0Time\u00a0Frame:\u00a0Week 12, Week 24, and Week 92\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Secondary Outcome Measures: Efficacy of LY3009104 in participants with moderate to severe plaque psoriasis. Measure: Psoriasis Area and Severity Index (PASI) [\u00a0Time\u00a0Frame:\u00a012 weeks\u00a0] [\u00a0Designated\u00a0as\u00a0safety\u00a0issue:\u00a0No\u00a0] Primary Outcome Measures: Further study details as provided by Eli Lilly and Company:",
    "textAfterTable": "\u00a0 Eligibility Ages Eligible for Study: \u00a0 18 Years and older Genders Eligible for Study: \u00a0 Both Accepts Healthy Volunteers: \u00a0 No Criteria Inclusion Criteria: You must have active chronic plaque psoriasis for at least 6 months prior to entry into the study You are a candidate for systemic therapy and/or phototherapy You must have active plaque psoriasis covering at least 12% body surface area You must have Psoriasis Area and Severity Index (PASI) score of at least 12 You must have Static Physician's Global Assessment (sPGA) score of at least 3 Exclusion Criteria: You must not have received a biologic agent/monoclonal antibody within 8 weeks prior to entry into the study You must not have prior treatment with an oral Janus kinase (JAK) inhibitor You must not have received a systemic psoriasis (Ps) therapy within 4 weeks prior to entry into the study You must not have received a",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}